LINUX FOR DRUGSOpen source software such as Linux and Android are crowdsourced, patent-free, affordable, and market-dominant. In brief, Open Source Pharma is:
1) crowdsourced and computer-driven drug discovery; 2) IT-enabled clinical trials with open data and crowdsourcing; and 3) generics manufacture Through conducting the world's first clinical trial and for neglected diseases, building platforms for international scientific collaboration, promoting citizen science, as well as working with patient communities, we aim to work towards an alternative, end-to-end pharmaceutical system and create the world's first open source drug. |
OUR GOALWe seek to create affordable new medicines in areas of public health need. We do so by using open source methodologies of computation, collaboration, crowdsourcing, transparency, and open intellectual property. Our goal is to cut costs by 90% and development time by 50% against the standard big pharma model. We will address areas where big pharma finds an insufficient market incentive to develop new cures.
|
|
OUR VISION
VISION
Medicine for all.
MISSION
Create a movement that includes existing initiatives and develops an alternative, comprehensive, open source pharmaceutical system driven by principles of openness, patient needs, and affordability.
OPERATING PRINCIPLES
Please note: The above statement was unanimously adopted by participants of the July 2014 Bellagio Center conference in their individual capacities. It does not necessarily represent the views of the organizations to which they belong.
Medicine for all.
MISSION
Create a movement that includes existing initiatives and develops an alternative, comprehensive, open source pharmaceutical system driven by principles of openness, patient needs, and affordability.
OPERATING PRINCIPLES
- Employ radical openness, sharing, and transparency.
- Leverage the global brainpower of the crowd.
- Adopt open and innovative approaches to the management of intellectual property and financing.
- Create monetary and nonmonetary reward systems for R&D that are alternatives to the prevailing proprietary model.
- Support open access to papers, data, and other research outputs.
- Convene and mobilise thought, opinion, and community leadership in reshaping R&D.
- Combine small, nimble, cost-effective facilitating structures able to harness the power of individuals and entities.
- Deliver affordable products.
- Place patients and their interests at the center of the R&D model and the pharmaceutical system.
- Develop a portfolio focused on critical gaps in global health where traditional market approaches are failing, e.g., anti-infectives.
Please note: The above statement was unanimously adopted by participants of the July 2014 Bellagio Center conference in their individual capacities. It does not necessarily represent the views of the organizations to which they belong.
